BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria

Reuters02-25 20:03

Feb 25 (Reuters) - Celldex Therapeutics Inc CLDX.O:

CELLDEX COMPLETES ENROLLMENT IN GLOBAL PHASE 3 STUDIES (EMBARQ-CSU1 AND EMBARQ-CSU2) OF BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIA
CELLDEX THERAPEUTICS INC - TOPLINE DATA EXPECTED Q4 2026
CELLDEX THERAPEUTICS INC - BLA SUBMISSION PLANNED FOR 2027

Source text: ID:nGNX4d81LP

Further company coverage: CLDX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614890690?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614890690","market":"us","top_or_hot":-1,"title":"BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria</title></head><body><p><span>Feb 25 (Reuters)</span><span> - </span>Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CLDX.O</span>:</p><ul><li><p>CELLDEX COMPLETES ENROLLMENT IN GLOBAL PHASE 3 STUDIES (EMBARQ-CSU1 AND EMBARQ-CSU2) OF BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIA</p></li><li><p>CELLDEX THERAPEUTICS INC - TOPLINE DATA EXPECTED Q4 2026</p></li><li><p>CELLDEX THERAPEUTICS INC - BLA SUBMISSION PLANNED FOR 2027</p></li></ul><p>Source text: <span>ID:nGNX4d81LP</span></p><p>Further company coverage: <span>CLDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous Urticaria</title></head><body><p><span>Feb 25 (Reuters)</span><span> - </span>Celldex <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>CLDX.O</span>:</p><ul><li><p>CELLDEX COMPLETES ENROLLMENT IN GLOBAL PHASE 3 STUDIES (EMBARQ-CSU1 AND EMBARQ-CSU2) OF BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIA</p></li><li><p>CELLDEX THERAPEUTICS INC - TOPLINE DATA EXPECTED Q4 2026</p></li><li><p>CELLDEX THERAPEUTICS INC - BLA SUBMISSION PLANNED FOR 2027</p></li></ul><p>Source text: <span>ID:nGNX4d81LP</span></p><p>Further company coverage: <span>CLDX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL0RL:1","article_id":"2614890690","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614890690","pubTimestamp":1772021011,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous UrticariaFeb 25 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CLDX":"塞德斯医疗"},"translate_title":"简介-Celldex完成Barzolvolimab治疗慢性自发性荨麻疹的全球3期研究（Embarq-Csu1和Embarq-Csu2）的入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLDX":0.9},"content_text":"BRIEF-Celldex Completes Enrollment In Global Phase 3 Studies (Embarq-Csu1 And Embarq-Csu2) Of Barzolvolimab In Chronic Spontaneous UrticariaFeb 25 (Reuters) - Celldex Therapeutics Inc CLDX.O:CELLDEX COMPLETES ENROLLMENT IN GLOBAL PHASE 3 STUDIES (EMBARQ-CSU1 AND EMBARQ-CSU2) OF BARZOLVOLIMAB IN CHRONIC SPONTANEOUS URTICARIACELLDEX THERAPEUTICS INC - TOPLINE DATA EXPECTED Q4 2026CELLDEX THERAPEUTICS INC - BLA SUBMISSION PLANNED FOR 2027Source text: ID:nGNX4d81LPFurther company coverage: CLDX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614890690","isCrawlerRequest":true}